1. Home
  2. YDKG vs TBPH Comparison

YDKG vs TBPH Comparison

Compare YDKG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YDKG
  • TBPH
  • Stock Information
  • Founded
  • YDKG 2005
  • TBPH 2013
  • Country
  • YDKG China
  • TBPH United States
  • Employees
  • YDKG N/A
  • TBPH N/A
  • Industry
  • YDKG Advertising
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • YDKG Consumer Discretionary
  • TBPH Health Care
  • Exchange
  • YDKG Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • YDKG 715.1M
  • TBPH 699.0M
  • IPO Year
  • YDKG N/A
  • TBPH N/A
  • Fundamental
  • Price
  • YDKG $1.55
  • TBPH $18.18
  • Analyst Decision
  • YDKG
  • TBPH Strong Buy
  • Analyst Count
  • YDKG 0
  • TBPH 4
  • Target Price
  • YDKG N/A
  • TBPH $24.25
  • AVG Volume (30 Days)
  • YDKG 2.5M
  • TBPH 427.4K
  • Earning Date
  • YDKG 11-17-2025
  • TBPH 11-10-2025
  • Dividend Yield
  • YDKG N/A
  • TBPH N/A
  • EPS Growth
  • YDKG N/A
  • TBPH N/A
  • EPS
  • YDKG N/A
  • TBPH 0.58
  • Revenue
  • YDKG $13,107,000.00
  • TBPH $80,327,000.00
  • Revenue This Year
  • YDKG N/A
  • TBPH $79.82
  • Revenue Next Year
  • YDKG N/A
  • TBPH N/A
  • P/E Ratio
  • YDKG N/A
  • TBPH $29.97
  • Revenue Growth
  • YDKG 2175.52
  • TBPH 27.12
  • 52 Week Low
  • YDKG $1.65
  • TBPH $7.90
  • 52 Week High
  • YDKG $472.00
  • TBPH $18.96
  • Technical
  • Relative Strength Index (RSI)
  • YDKG N/A
  • TBPH 71.85
  • Support Level
  • YDKG N/A
  • TBPH $16.82
  • Resistance Level
  • YDKG N/A
  • TBPH $18.21
  • Average True Range (ATR)
  • YDKG 0.00
  • TBPH 0.88
  • MACD
  • YDKG 0.00
  • TBPH 0.35
  • Stochastic Oscillator
  • YDKG 0.00
  • TBPH 85.83

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: